On September 7, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that Phase 2 data evaluating the safety of suprachoroidal administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (IL/CM)) will be presented at the ESMO (Free ESMO Whitepaper) 2022 Congress, being held September 9-13, 2022, in Paris, France (Press release, Aura Biosciences, SEP 7, 2022, View Source [SID1234619184]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for ESMO (Free ESMO Whitepaper) 2022 poster presentation:

Title: A Phase 2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration
Presenter: Hakan Demirci, University of Michigan
Session: Melanoma and Other Skin Tumors
Presentation #: 842P
Date/Time: Saturday, September 10, 2022, at 2:15 p.m. CEST

The presentation will be available on the "Scientific Presentations" section of "VDC Platform" page of the Aura Biosciences website on Saturday, September 10, 2022.